Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Nature Communications

Volumn 7, Issue , 2016, Pages

  Bottos, Alessia ^a   Gotthardt, Dagmar ^b   Gill, Jason W ^a   Gattelli, Albana ^a   Frei, Anna ^a,c   Tzankov, Alexandar ^d   Sexl, Veronika ^b   Wodnar Filipowicz, Aleksandra ^c   Hynes, Nancy E ^a,c  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; JANUS KINASE; RUXOLITINIB; STAT PROTEIN; JANUS KINASE INHIBITOR;

BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; CYTOLOGY; IMMUNOASSAY; INHIBITION; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MOLECULARLY TARGETED THERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; TUMOR BIOPSY; TUMOR IMMUNITY; ANIMAL; BIOLOGICAL MODEL; BONE TUMOR; BREAST TUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SECONDARY;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; INTERLEUKIN-15; JANUS KINASE INHIBITORS; JANUS KINASES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MODELS, BIOLOGICAL; STAT TRANSCRIPTION FACTORS;

EID: 84978832068     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12258     Document Type: Article

References (70)

1. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004).
2. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
3. Walker, S. R. et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res. 7, 966-976 (2009).
4. Sansone, P. & Bromberg, J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 30, 1005-1014 (2012).
5. Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735 (2011).
6. Britschgi, A. et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer cell 22, 796-811 (2012).
7. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117-1127 (2010).
8. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787-798 (2012).
9. Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426-435 (2015).
10. Quintas-Cardama, A. & Verstovsek, S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res. 19, 1933-1940 (2013).
11. Maxmen, A. The hard facts. Nature 485, S50-S51 (2012).
12. Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411-425 (2011).
13. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
14. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
15. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
16. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
17. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
18. Smith, H. A. & Kang, Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91, 411-429 (2013).
19. Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
20. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
21. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
22. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
23. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
24. Mahmoud, S. M. et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949-1955 (2011).
25. Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536-1543 (2014).
26. Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49 (2011).
27. Smyth, M. J. et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501-510 (2005).
28. Krasnova, Y., Putz, E. M., Smyth, M. J. & Souza-Fonseca-Guimaraes, F. Bench to bedside: NK cells and control of metastasis. Clin. Immunol. S1521-S6616 30050-4 (2015).
29. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005).
30. Gotthardt, D. et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124, 2370-2379 (2014).
31. Lee, C. K. et al. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165, 3571-3577 (2000).
32. Yamamoto, K., Shibata, F., Miyasaka, N. & Miura, O. The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem. Biophys. Res. Commun. 297, 1245-1252 (2002).
33. Eckelhart, E. et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117, 1565-1573 (2011).
34. Gotthardt, D. et al. STAT5 is a key regulator in NK Cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 6, 414-429 (2016).
35. Quintas-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109-3117 (2010).
36. Schindler, C., Levy, D. E. & Decker, T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059-20063 (2007).
37. Huntington, N. D., Vosshenrich, C. A. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703-714 (2007).
38. Hayakawa, Y. & Smyth, M. J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517-1524 (2006).
39. Chiossone, L. et al. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113, 5488-5496 (2009).
40. Baffert, F. et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 9, 1945-1955 (2010).
41. Grundschober, E. et al. Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia 28, 1918-1922 (2014).
42. Carson, W. E. et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403 (1994).
43. Huntington, N. D. The unconventional expression of IL-15 and its role in NK cell homeostasis. Imkmunol. Cell Biol. 92, 210-213 (2014).
44. Hurwitz, H. I. et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol. 33, 4039-4047 (2015).
45. Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogeneaddicted cancer cells. Cancer Cell 26, 207-221 (2014).
46. Toso, A. et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75-89 (2014).
47. Mascarenhas, J. & Hoffman, R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121, 4832-4837 (2013).
48. Parampalli Yajnanarayana, S. et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br. J. Haematol. 169, 824-833 (2015).
49. Schonberg, K. et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 75, 2187-2199 (2015).
50. Heine, A. et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122, 1192-1202 (2013).
51. Heine, A., Brossart, P. & Wolf, D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122, 3843-3844 (2013).
52. Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224-1231 (2012).
53. Mamessier, E. et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609-3622 (2011).
54. Chow, M. T. et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 72, 5721-5732 (2012).
55. Bui, J. D. & Schreiber, R. D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19, 203-208 (2007).
56. Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795-1799 (2000).
57. Miller, C. P. et al. JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol. Res. 2, 301-306 (2014).
58. Allegrezza, M. J. et al. Il-15 agonists overcome the immunosuppressive effects of mek inhibitors. Cancer Res. 76, 2561-2572 (2016).
59. Krusch, M. et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J. Immunol. 183, 8286-8294 (2009).
60. Johnston, J. A. et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl Acad. Sci. USA 92, 8705-8709 (1995).
61. Becknell, B. & Caligiuri, M. A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 86, 209-239 (2005).
62. Ljunggren, H. G. & Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329-339 (2007).
63. Meier, C. et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod. Pathol. 22, 476-487 (2009).
64. Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427-1429 (1995).
65. Wagner, K. U. et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell Biol. 24, 5510-5520 (2004).
66. Koo, G. C. & Peppard, J. R. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3, 301-303 (1984).
67. Lelekakis, M. et al. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163-170 (1999).
68. Liu, H. et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107, 18115-18120 (2010).
69. Gattelli, A. et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol. Med. 5, 1335-1350 (2013).
70. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B. & Hennighausen, L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl Acad. Sci. USA 92, 8831-8835 (1995).